sorafenib has been researched along with Squamous Cell Carcinoma of Head and Neck in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Teijeiro, S; Calvo, F; Cutillas, P; Garcia-Pedrero, JM; Hermida-Prado, F; Hijazi, M; Llames, S; Montoro-Jimenez, I; Pevida, M; Prieto-Fernandez, L; Rodrigo, JP; Villaronga, MLA | 1 |
| Dikomey, E; Gal, A; Gleißner, L; Grénman, R; Grob, TJ; Knecht, R; Kriegs, M; Laban, S; Petersen, C; Steinmeister, L | 1 |
| Bhatt, VR; Ganti, AK | 1 |
| Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M | 1 |
| Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL | 1 |
| Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C | 1 |
| Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W | 1 |
1 trial(s) available for sorafenib and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
6 other study(ies) available for sorafenib and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Driving role of head and neck cancer cell secretome on the invasion of stromal fibroblasts: Mechanistic insights by phosphoproteomics.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Fibroblasts; Head and Neck Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Secretome; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2023 |
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Repair; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Radiation-Sensitizing Agents; raf Kinases; Sorafenib; Squamous Cell Carcinoma of Head and Neck | 2013 |
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Squamous Cell Carcinoma of Head and Neck | 2014 |
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Hyperplasia; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2015 |
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Indoles; Molecular Targeted Therapy; Niacinamide; Papillomaviridae; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib; TOR Serine-Threonine Kinases | 2015 |
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Radiation-Sensitizing Agents; Risk Assessment; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib | 2017 |